drugset / Trial / NCT06845943
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
Timeline
- Start
- 2025-03-04
- Primary completion
- 2025-10-22
- Completion
- 2027-12
Outcome
Outcome not reported
Stopped (Business): “Business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCR-188 | Unknown | — | Subcutaneous |